Where does Teva Pharmaceuticals International GMBH rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Teva Pharmaceuticals International GMBH ranks #6,080 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Teva Pharmaceuticals International GMBH hold?

Teva Pharmaceuticals International GMBH holds 56 US utility patents granted between 2015 and 2024, spanning 14 technology areas.

What is Teva Pharmaceuticals International GMBH's Innovation Score?

Teva Pharmaceuticals International GMBH has an Innovation Score of 44.3 out of 100 (top 26% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Teva Pharmaceuticals International GMBH focus on?

Teva Pharmaceuticals International GMBH's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 39 patents, ranking #473 of 6,058 assignees active in that subclass. Grants appear in 14 CPC subclasses total.

Is Teva Pharmaceuticals International GMBH's patent grant rate increasing or decreasing?

Teva Pharmaceuticals International GMBH's recent grant velocity is -13% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Teva Pharmaceuticals International GMBH's patents?

Teva Pharmaceuticals International GMBH's patents average 19.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Teva Pharmaceuticals International GMBH

Q: How is the Teva Pharmaceuticals International GMBH patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 56 granted patents across 14 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Teva ranks #6,080 of 49,997 tracked US assignees by granted-patent volume, with 56 patents across 14 technology areas.

#6,080
of 49,997 US assignees by volume: Top 26%
by Innovation Score (44.3/100): 19.7
avg claims per patent: -13%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R6080 · Foreign Corporation #6,080 · 56 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 56 grants
UPPER-Q #6,080/49,997
PHOTO-FINISH Shantou P&C Plastic…
CPC-FOCUS A61P · 14 areas
INNOV-PAR 44.3/100
CLAIMS-RICH 19.7 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -13% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Shantou P&C Plastic Products Company Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Teva’s 44.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 14.0 pts (32%) Velocity 5.3 pts (12%) Breadth 13.2 pts (30%) Claim depth 11.8 pts (27%)

Qualcomm Incorporated · highest

85
eLux · near

44
Shenzhen Eigate… · near

44
TD Ameritrade IP · near

44
Teva Pharmaceuticals… · this assignee

44
Traeger Pellet Grills · near

44
3D Lighting… · lowest

7

What this shows Teva's Innovation Score is 44.3/100 (top 26% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Teva?

Each dot is one of Teva’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Teva’s own 19.7 claims/patent is ABOVE the 13.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Teva vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Teva's grants concentrate

Teva Pharmaceuticals International GMBH is a focused PatentsView assignee: 14 CPC subclasses with 69.6% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (10 grants) versus a trough of 1 in 2015. By volume, Teva sits between Shantou P&C Plastic Products Company Limited and UNIVERSITÉ DE Lille.

Teva's three-year grant acceleration

Teva Pharmaceuticals International GMBH shows 15 grants in 2022–2024 against only 19 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Shantou P&C Plast…

56
Sigma-aldrich

56
Silgan Containers

56
Tendyron

56
TQ Delta

56
Toshiba Carrier

56
Ultratec

56
UniversitÉ DE Lil…

56
Teva Pharmaceutic… ◀

56

What this shows Teva holds 56 patents at rank #6,080, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Teva

By rank, the assignees closest to #6,080 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Teva's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Teva, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Teva ranks #473 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (44 here).

eLux, Inc. 44 Shenzhen Eigate Technology Co., Ltd. 44 Traeger Pellet Grills, LLC 44 TD Ameritrade IP Company, Inc. 44

Similar claim depth

Nearest assignees by average claims per patent (19.7 here).

Aseko, Inc. 19.7 avg Crucible Intellectual Property, LLC 19.7 avg Damaka, Inc. 19.7 avg Zazzle Inc. 19.7 avg

Teva's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 26% higher than 74% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Teva Pharmaceuticals International GMBH patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	1.8%
2016	5	8.9%
2017	10	17.9%
2018	6	10.7%
2019	8	14.3%
2020	6	10.7%
2021	5	8.9%
2022	4	7.1%
2023	6	10.7%
2024	5	8.9%

Which technologies does Teva Pharmaceuticals International GMBH patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 39

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 32

C07D - Heterocyclic Compounds 19

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 16

C07K - Peptides 16

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 7

C07C - Acyclic OR Carbocyclic Compounds 6

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 3

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 3

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 2

Y10T - Technical Subjects Covered BY Former US Classification 1

A61B - DIAGNOSIS; SURGERY; Identification 1

B65D - Containers FOR Storage OR Transport OF Articles OR Materials, e.g. Bags, Barrels, Bottles, Boxes, Cans, Cartons, Crates, Drums, Jars, Tanks, Hoppers, Forwarding CONTAINERS; Accessories, Closures, OR Fittings THEREFOR; Packaging ELEMENTS; Packages 1

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

Top 14 of 14 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Teva Pharmaceuticals International GMBH's patent record in context - here's where to go next.

Teva Pharmaceuticals International GMBH's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 69.6% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #6,080 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Teva Pharmaceuticals International GMBH against Shantou P&C Plastic Products Company Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 44.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.